SLC5A2 and COVID-19: The DARE-19 trial compared the SGLT2 inhibitor dapagliflozin 10 mg once daily with placebo in 1250 patients hospitalised with COVID-19 who had at least one cardiometabolic risk factor (with or without diabetes) but were not critically ill.17